about the forum

The CHI 2011 Annual Meeting brought together executives from biotechnology, medical device, diagnostics and pharmaceutical companies as well as leaders from the state’s academic research community with policy makers to discuss critical issues and opportunities facing the biomedical community.


The meeting provided a platform for dialogue on a host of issues, including:

  • The impact of future healthcare coverage on the biomedical industry;
  • Case studies on innovation and access in oncology;
  • Obstacles and opportunities in anti-infectives and vaccines;
  • The future of follow-on biologics;
  • And the reimbursement landscape for novel diagnostics.

Featured panel discussions

Oncology: A Case Study in Innovation & Access

Moderator: Dr. Anthony Coles, CEO, Onyx Pharmaceuticals
Dr. Robert Figlin, Head of Oncology, Cedears Sinai Health Systems
Dr. Risa Stack, Partner, Kleiner Perkins Caufield & Byers
Nancy Brandish Myers, President and Founder, Catalyst Healthcare Consulting
David Nelson, DEO, Epic Sciences and Board Member, Clearity Foundation

From the promise of personalized medicine to a shift toward more targeted treatments, panelists discuss the development of new cancer therapies, diagnostics and the innovations that lie ahead. The panel also explores how public policy shapes, fosters and creates challenges for biomedical innovation in oncology.

 

 

Competitiveness and Regulation: The FDA and the Future of America’s Biomedical Industry

Moderator: Dr. David L. Gollaher, President & CEO, CHI
Simon Goodall, Partner & Managing Director, Boston Consulting Group
Ronald Warren, Principal Consultant, Medical Device Consultants
Marti Conger, Patient Advocate
Paul Hastings, President & CEO, OncoMed
Ferolyn Powell, Divisional Vice President and General Manager, Structural Heart, Abbott Vascular

Based on an analysis of published data, the California Healthcare Institute and Boston Consulting Group study, "Competitiveness and Regulation: The FDA and The Future of America's Biomedical Industry," confirms a common view of the FDA: namely, that the agency represents a serious, and growing, barrier to innovation. Industry executives, analysts and a patient advocate discuss their own views on the subject of regulatory review and access to innovative therapies.

 
Click here to download full report

 

Infectious Diseases: Obstacles and Opportunities
in Anti-infectives and Vaccine Development

Moderator: Dr. Peter Milner, Executive Vice President, Optivia Biotechnology
Dr. John Freund, Founder, Skyline Ventures
Dr. Steve Projan, Senior Vice-President of R&D, MedImmune
Rick Winningham, CEO, Theravance
Dr. Lars Wegner, Vice-President, Commercial Affairs, Bavarian Nordic

Between five and 10 of all hospital patients develop an infection leading to an increase of about $5 billion in annual healthcare costs in the United States. This panel discusses the obstacles and opportunities in anti-infective and vaccine development.